Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 10.23
NAS:CYNO's Cash-to-Debt is ranked higher than
62% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. NAS:CYNO: 10.23 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CYNO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.93  Med: 34.18 Max: 501.94
Current: 10.23
0.93
501.94
Equity-to-Asset 0.78
NAS:CYNO's Equity-to-Asset is ranked higher than
77% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NAS:CYNO: 0.78 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CYNO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.4  Med: 0.79 Max: 0.85
Current: 0.78
0.4
0.85
Interest Coverage 17.49
NAS:CYNO's Interest Coverage is ranked lower than
68% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. NAS:CYNO: 17.49 )
Ranked among companies with meaningful Interest Coverage only.
NAS:CYNO' s Interest Coverage Range Over the Past 10 Years
Min: 14.7  Med: N/A Max: N/A
Current: 17.49
Piotroski F-Score: 7
Altman Z-Score: 8.82
Beneish M-Score: -2.72
WACC vs ROIC
13.45%
5.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 6.31
NAS:CYNO's Operating Margin % is ranked higher than
60% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. NAS:CYNO: 6.31 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CYNO' s Operating Margin % Range Over the Past 10 Years
Min: -27.9  Med: 6.79 Max: 15.75
Current: 6.31
-27.9
15.75
Net Margin % 3.28
NAS:CYNO's Net Margin % is ranked higher than
56% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. NAS:CYNO: 3.28 )
Ranked among companies with meaningful Net Margin % only.
NAS:CYNO' s Net Margin % Range Over the Past 10 Years
Min: -31.25  Med: 3.97 Max: 11.67
Current: 3.28
-31.25
11.67
ROE % 3.28
NAS:CYNO's ROE % is ranked higher than
54% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. NAS:CYNO: 3.28 )
Ranked among companies with meaningful ROE % only.
NAS:CYNO' s ROE % Range Over the Past 10 Years
Min: -17.23  Med: 3.73 Max: 14.04
Current: 3.28
-17.23
14.04
ROA % 2.55
NAS:CYNO's ROA % is ranked higher than
60% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. NAS:CYNO: 2.55 )
Ranked among companies with meaningful ROA % only.
NAS:CYNO' s ROA % Range Over the Past 10 Years
Min: -14.3  Med: 2.86 Max: 11.19
Current: 2.55
-14.3
11.19
ROC (Joel Greenblatt) % 30.48
NAS:CYNO's ROC (Joel Greenblatt) % is ranked higher than
76% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. NAS:CYNO: 30.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CYNO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -54.37  Med: 31.05 Max: 60.47
Current: 30.48
-54.37
60.47
3-Year Revenue Growth Rate 16.10
NAS:CYNO's 3-Year Revenue Growth Rate is ranked higher than
82% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. NAS:CYNO: 16.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CYNO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.1  Med: 14.4 Max: 24.8
Current: 16.1
-13.1
24.8
3-Year EBITDA Growth Rate 128.40
NAS:CYNO's 3-Year EBITDA Growth Rate is ranked higher than
98% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. NAS:CYNO: 128.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CYNO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -74  Med: 16.1 Max: 128.4
Current: 128.4
-74
128.4
GuruFocus has detected 4 Warning Signs with Cynosure Inc $NAS:CYNO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CYNO's 10-Y Financials

Financials (Next Earnings Date: 2017-05-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CYNO Guru Trades in Q1 2016

Steven Cohen 535,400 sh (New)
Joel Greenblatt 58,566 sh (New)
Paul Tudor Jones 5,052 sh (New)
Ken Fisher 114,213 sh (unchged)
Chuck Royce Sold Out
Mario Gabelli 10,581 sh (-2.43%)
Robert Olstein 49,600 sh (-11.43%)
» More
Q2 2016

CYNO Guru Trades in Q2 2016

Jim Simons 270,571 sh (New)
Jim Chanos 73,367 sh (New)
Paul Tudor Jones 7,500 sh (+48.46%)
Mario Gabelli 10,581 sh (unchged)
Ken Fisher 96,170 sh (-15.80%)
Steven Cohen 439,900 sh (-17.84%)
Robert Olstein 30,375 sh (-38.76%)
Joel Greenblatt 30,088 sh (-48.63%)
» More
Q3 2016

CYNO Guru Trades in Q3 2016

Steven Cohen Sold Out
Jim Chanos Sold Out
Robert Olstein 29,875 sh (-1.65%)
Mario Gabelli 9,581 sh (-9.45%)
Jim Simons 229,571 sh (-15.15%)
Ken Fisher 73,253 sh (-23.83%)
Paul Tudor Jones 5,152 sh (-31.31%)
Joel Greenblatt 19,134 sh (-36.41%)
» More
Q4 2016

CYNO Guru Trades in Q4 2016

Jeremy Grantham 50,000 sh (New)
Paul Tudor Jones 6,300 sh (+22.28%)
Robert Olstein 35,525 sh (+18.91%)
Mario Gabelli 9,581 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Ken Fisher 38,635 sh (-47.26%)
» More
» Details

Insider Trades

Latest Guru Trades with CYNO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:OTCPK:IOBCF, NAS:INGN, NAS:BABY, NAS:SPNC, NYSE:ITGR, OTCPK:NHNKY, NAS:CNMD, NAS:MDXG, NAS:VASC, NAS:ZLTQ, NAS:CSII, NAS:KTWO, NAS:LIVN, NAS:OFIX, OTCPK:SBMAF, OTCPK:MZRTF, NAS:GNMK, NYSE:CRY, OTCPK:NMRD, NAS:XENT » details
Traded in other countries:C9S.Germany,
Headquarter Location:USA
Cynosure Inc develops & markets aesthetic treatment systems that enable plastic surgeons, dermatologists & other medical practitioners to perform non-invasive & minimally invasive procedures to remove hair, treat vascular & benign pigmented lesion, etc.

Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as it expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.

Top Ranked Articles about Cynosure Inc

Steven Cohen Invests in Cynosure Purchase makes him company's leading guru shareholder
Steven Cohen (Trades, Portfolio) of Point72 Asset Management invested in a 731,500-share stake in Cynosure Inc. (NASDAQ:CYNO), a Westford, Massachusetts-based company that manufactures aesthetic medical devices, for a price of $46.27 per share on April 25. Read more...

Ratios

vs
industry
vs
history
PE Ratio 111.86
CYNO's PE Ratio is ranked lower than
90% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. CYNO: 111.86 )
Ranked among companies with meaningful PE Ratio only.
CYNO' s PE Ratio Range Over the Past 10 Years
Min: 10.05  Med: 39.37 Max: 629.6
Current: 111.86
10.05
629.6
Forward PE Ratio 41.84
CYNO's Forward PE Ratio is ranked lower than
90% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. CYNO: 41.84 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 111.86
CYNO's PE Ratio without NRI is ranked lower than
90% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. CYNO: 111.86 )
Ranked among companies with meaningful PE Ratio without NRI only.
CYNO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.05  Med: 39.37 Max: 629.6
Current: 111.86
10.05
629.6
Price-to-Owner-Earnings 60.77
CYNO's Price-to-Owner-Earnings is ranked lower than
76% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.96 vs. CYNO: 60.77 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CYNO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 16.47  Med: 37.51 Max: 128.24
Current: 60.77
16.47
128.24
PB Ratio 3.46
CYNO's PB Ratio is ranked lower than
55% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. CYNO: 3.46 )
Ranked among companies with meaningful PB Ratio only.
CYNO' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 2.03 Max: 4.67
Current: 3.46
0.59
4.67
PS Ratio 3.60
CYNO's PS Ratio is ranked lower than
56% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. CYNO: 3.60 )
Ranked among companies with meaningful PS Ratio only.
CYNO' s PS Ratio Range Over the Past 10 Years
Min: 0.69  Med: 2.34 Max: 4.54
Current: 3.6
0.69
4.54
Price-to-Free-Cash-Flow 49.77
CYNO's Price-to-Free-Cash-Flow is ranked lower than
74% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. CYNO: 49.77 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CYNO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.43  Med: 32.7 Max: 164.5
Current: 49.77
12.43
164.5
Price-to-Operating-Cash-Flow 34.79
CYNO's Price-to-Operating-Cash-Flow is ranked lower than
76% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. CYNO: 34.79 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CYNO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.09  Med: 23.82 Max: 1210.77
Current: 34.79
10.09
1210.77
EV-to-EBIT 51.57
CYNO's EV-to-EBIT is ranked lower than
87% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. CYNO: 51.57 )
Ranked among companies with meaningful EV-to-EBIT only.
CYNO' s EV-to-EBIT Range Over the Past 10 Years
Min: -182.8  Med: 26.3 Max: 312.4
Current: 51.57
-182.8
312.4
EV-to-EBITDA 29.37
CYNO's EV-to-EBITDA is ranked lower than
75% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. CYNO: 29.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYNO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -305.5  Med: 17.4 Max: 440.8
Current: 29.37
-305.5
440.8
PEG Ratio 2.80
CYNO's PEG Ratio is ranked lower than
58% of the 83 Companies
in the Global Medical Devices industry.

( Industry Median: 2.52 vs. CYNO: 2.80 )
Ranked among companies with meaningful PEG Ratio only.
CYNO' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.19
Current: 2.8
0
3.19
Shiller PE Ratio 220.82
CYNO's Shiller PE Ratio is ranked lower than
90% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.41 vs. CYNO: 220.82 )
Ranked among companies with meaningful Shiller PE Ratio only.
CYNO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 92  Med: 163.65 Max: 221
Current: 220.82
92
221
Current Ratio 3.21
CYNO's Current Ratio is ranked higher than
63% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. CYNO: 3.21 )
Ranked among companies with meaningful Current Ratio only.
CYNO' s Current Ratio Range Over the Past 10 Years
Min: 1.44  Med: 4.09 Max: 6.29
Current: 3.21
1.44
6.29
Quick Ratio 2.49
CYNO's Quick Ratio is ranked higher than
63% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. CYNO: 2.49 )
Ranked among companies with meaningful Quick Ratio only.
CYNO' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 3.17 Max: 5.21
Current: 2.49
0.8
5.21
Days Inventory 167.48
CYNO's Days Inventory is ranked lower than
64% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. CYNO: 167.48 )
Ranked among companies with meaningful Days Inventory only.
CYNO' s Days Inventory Range Over the Past 10 Years
Min: 157.29  Med: 175.26 Max: 289.61
Current: 167.48
157.29
289.61
Days Sales Outstanding 35.44
CYNO's Days Sales Outstanding is ranked higher than
90% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. CYNO: 35.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYNO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.44  Med: 50.25 Max: 70.83
Current: 35.44
35.44
70.83
Days Payable 50.91
CYNO's Days Payable is ranked lower than
55% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. CYNO: 50.91 )
Ranked among companies with meaningful Days Payable only.
CYNO' s Days Payable Range Over the Past 10 Years
Min: 23.04  Med: 52.12 Max: 84.75
Current: 50.91
23.04
84.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.10
CYNO's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. CYNO: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYNO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.1  Med: -12 Max: 0.4
Current: -3.1
-29.1
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 22.76
CYNO's Price-to-Net-Cash is ranked lower than
60% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. CYNO: 22.76 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CYNO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.43  Med: 10.81 Max: 73.23
Current: 22.76
2.43
73.23
Price-to-Net-Current-Asset-Value 7.59
CYNO's Price-to-Net-Current-Asset-Value is ranked lower than
54% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. CYNO: 7.59 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CYNO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.93  Med: 3.61 Max: 7.59
Current: 7.59
0.93
7.59
Price-to-Tangible-Book 5.02
CYNO's Price-to-Tangible-Book is ranked lower than
58% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. CYNO: 5.02 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CYNO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.72  Med: 2.88 Max: 5.02
Current: 5.02
0.72
5.02
Price-to-Intrinsic-Value-Projected-FCF 2.65
CYNO's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
61% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. CYNO: 2.65 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CYNO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.04  Med: 1.63 Max: 2.65
Current: 2.65
1.04
2.65
Price-to-Median-PS-Value 1.54
CYNO's Price-to-Median-PS-Value is ranked lower than
79% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. CYNO: 1.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYNO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 1.01 Max: 2.14
Current: 1.54
0.31
2.14
Price-to-Graham-Number 4.99
CYNO's Price-to-Graham-Number is ranked lower than
80% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. CYNO: 4.99 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CYNO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.56  Med: 1.75 Max: 4.99
Current: 4.99
0.56
4.99
Earnings Yield (Greenblatt) % 1.94
CYNO's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. CYNO: 1.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYNO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 3.5 Max: 44.6
Current: 1.94
0.3
44.6

More Statistics

Revenue (TTM) (Mil) $433.5
EPS (TTM) $ 0.59
Beta1.89
Short Percentage of Float9.73%
52-Week Range $39.90 - 66.65
Shares Outstanding (Mil)24.10

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 1.58
EPS without NRI ($) 1.58
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CYNO

Headlines

Articles On GuruFocus.com
Steven Cohen Invests in Cynosure Apr 26 2016 
Robert Olstein's Olstein Strategic Opportunities Fund Q4 Commentary Mar 11 2016 
Cynosure Inc. (CYNO) CFO Timothy W Baker buys 2,500 Shares Feb 27 2009 
Cynosure Inc. (CYNO) CEO Michael R Davin buys 2,500 Shares Feb 27 2009 
Cynosure: A Value Play on Vanity Jan 18 2009 

More From Other Websites
Can Anyone Challenge Allergan In Medical-Aesthetics Market? Mar 24 2017
Hologic Completes Cynosure Buyout, Boosts Core Business Mar 23 2017
Penn National Gaming Set to Join S&P SmallCap 600 Mar 22 2017
MRLB U.S. Sales Jump 38% As Aesthetic Market Heats Up Mar 22 2017
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Cynosure, Inc. - CYNO Feb 28 2017
Medtronic Earnings Rebound in Third Quarter, Shares Climb Feb 21 2017
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cynosure, Inc. And... Feb 16 2017
CYNOSURE, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by... Feb 16 2017
Harwood Feffer LLP Announces Investigation of Cynosure, Inc. Feb 15 2017
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cynosure, Inc.... Feb 15 2017
Hologic to Acquire Cynosure for $1.65 Billion Feb 15 2017
Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal Feb 15 2017
CYNOSURE, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Feb 14 2017
Why Cynosure, RetailMeNot, and TransUnion Jumped Today Feb 14 2017
Hologic Follows Allergan, Buying Body-Sculptor Cynosure For $1.65 Bil Feb 14 2017
ETFs with exposure to Cynosure, Inc. : February 14, 2017 Feb 14 2017
Here's Why Cynosure, Inc. is Soaring Today Feb 14 2017
Hologic to buy Cynosure to expand into medical aesthetics Feb 14 2017
Hologic will snap up Westford-based Cynosure in $1.65B deal Feb 14 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of... Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)